Scarica l'app Stockscreener
3.99
13.45%
-0.62
Dopo l'orario di chiusura:
3.99
Adagene Inc Adr Borsa (ADAG) Ultime notizie
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Leerink raises Adagene stock price target to $8 on combination data - Investing.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - tipranks.com
Adagene reports 31% response rate in colorectal cancer trial - Investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
New and existing investors back Adagene’s $70M ADS sale - Stock Titan
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Adagene and Incyte target hard-to-treat colorectal cancer - Stock Titan
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - bitget.com
Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan
Cancer drug candidate shows 29% response rate as Adagene funds run to 2028 - Stock Titan
Empowering Investor Success - Morningstar
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6% - marketbeat.com
ETFs Investing in Adagene, Inc. Sponsored ADR Stocks - tradingview.com
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
AirBoss of America (OTCMKTS:ABSSF) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Alibaba Group (NYSE:BABA) Stock Price Down 2% on Analyst Downgrade - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Hunting (LON:HTG) Share Price Passes Above Two Hundred Day Moving Average – What’s Next? - Defense World
Adagene (NASDAQ:ADAG) Raised to Hold at Wall Street Zen - MarketBeat
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - wahanariau.com
Adagene Inc. (NASDAQ: ADAG) insider reports 2.39M shares, 5.1% stake - Stock Titan
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Adagene Inc. (ADAG) CEO Peter Luo reports options, RSUs and shares in Form 3 - Stock Titan
Adagene (ADAG) HR executive Form 3 details options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
Adagene Inc. (ADAG) director lists time and performance stock options - Stock Titan
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Bitget
Experimental cancer antibody muzastotug in colon and liver trials at AACR 2026 - Stock Titan
Adagene Inc. (ADAG) director discloses 25,000 shares and 65,000 options - Stock Titan
Adagene’s Muzastotug (ADG126) to be Highlighted in Two - GlobeNewswire
Adagene (ADAG) to Release Earnings on Monday - MarketBeat
Adagene Spotlights ADG126 at Leerink, Teases New MSS Colorectal Cancer Data Update Soon - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 24.5% in February - MarketBeat
Purple Biotech (PPBT) to Release Quarterly Earnings on Monday - Defense World
Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk - MarketBeat
Comparing KALA BIO (NASDAQ:KALA) and Adagene (NASDAQ:ADAG) - Defense World
Adagene to Participate in Two Upcoming Investor Conferences - The Manila Times
Adagene sets Oppenheimer, Leerink fireside chats for Feb. 25, March 9 - Stock Titan
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders - TradingView
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Rises By 283.2% - Defense World
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 283.2% - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):